University of Chinese Academy of Sciences, Beijing, 100049, People's Republic of China.
Key Laboratory of Biopharmaceutical Production & Formulation Engineering, PLA and State Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, No.1 Bei-er-tiao, Zhong-guan-cun, Haidian, Beijing, 100190, People's Republic of China.
Glycoconj J. 2018 Oct;35(5):451-459. doi: 10.1007/s10719-018-9830-y. Epub 2018 Jul 26.
Porcine circovirus type 2 (PCV2)-associated diseases have led to huge economic losses in pig industry. Our laboratory previously found that conjugation of chitosan oligosaccharides (COS) enhanced the immunogenicity of PCV2 vaccine against infectious pathogens. In this study, an effective adjuvant system was developed by covalent conjugation of COS via a carrier protein (Ovalbumin, OVA) to further increase the immunogenicity of vaccine. Its effect on dendritic cells maturation was assessed in vitro and its immunogenicity was investigated in mice. The results indicated that, as compared to the PCV2 and COS-PCV2, COS-OVA-PCV2 stimulated dendritic cells to express higher maturation markers (CD80, CD86, CD40 and MHC class II) and remarkably promoted both humoral and cellular immunity against PCV2 by enhancing the lymphocyte proliferation and inducing a mixed Th1/Th2 response, including the increased production of PCV2-specific antibodies and raised levels of inflammatory cytokines. Furthermore, it displayed better immune-stimulating effects than the physical mixture of vaccine and ISA206 (a commercialized adjuvant). In conclusion, conjugation of COS via a carrier protein might be a promising strategy to enhance the immunogenicity of vaccines.
猪圆环病毒 2 型（PCV2）相关疾病给养猪业造成了巨大的经济损失。本实验室先前发现，壳聚糖寡糖（COS）的缀合增强了 PCV2 疫苗对传染性病原体的免疫原性。在这项研究中，通过载体蛋白（卵清蛋白，OVA）将 COS 进行共价缀合，开发了一种有效的佐剂系统，以进一步提高疫苗的免疫原性。在体外评估了其对树突状细胞成熟的影响，并在小鼠中研究了其免疫原性。结果表明，与 PCV2 和 COS-PCV2 相比，COS-OVA-PCV2 刺激树突状细胞表达更高的成熟标志物（CD80、CD86、CD40 和 MHC Ⅱ类），并通过增强淋巴细胞增殖和诱导混合 Th1/Th2 反应，显著促进针对 PCV2 的体液和细胞免疫，包括增加 PCV2 特异性抗体的产生和提高炎症细胞因子水平。此外，它比疫苗和 ISA206（一种商业化佐剂）的物理混合物具有更好的免疫刺激作用。总之，通过载体蛋白将 COS 缀合可能是增强疫苗免疫原性的一种有前途的策略。
